EU researchers discuss latest optometry research at City workshop
Workshop featured a variety of speakers and a Dean’s Lecture from Dr Pearse Keane on the Moorfields – DeepMind collaboration
Optometry and visual science researchers from two prestigious EU-funded programmes came to City, University of London in March for a four day workshop to share the latest research in the area and hear from others working in the field.
Organised by Dr Susan Bryan and Lee Jones from the Crabb Lab in the Division of Optometry and Visual Science at City, the workshop included more than 25 early stage researchers from Netherlands, Germany, France, UK and Finland who are involved in the European Glaucoma Research Training Program (EGRET) and EGRETplus. Both projects received funding from the European Union’s Horizon 2020 research and innovation programme.
Across the four days the workshop featured a variety of speakers, with early stage researchers taking part in workshops that also saw them present interim results from their PhD studies to glaucoma specialists from Moorfields NHS Trust and Guy’s and St Thomas NHS Trust.
In particular, the workshop led by the Crabb Lab covered data analysis and statistics, and also incorporated a Dean’s Lecture from Dr Pearse Keane, a consultant ophthalmologist at Moorfields Eye Hospital and an NIHR clinical scientist at the UCL Institute of Ophthalmology on the Moorfields – DeepMind collaboration. In the lecture Dr Keane discussed how artificial intelligence may help clinicians to diagnose ocular diseases at a much earlier stage than current technologies. The workshop involved social events including a trip to the Tower of London.
Professor David Crabb, Professor of Statistics and Vision Research in the School of Health Sciences at City, University of London, said:
“It was great to welcome fellow researchers from the EGRET programmes to London to not only share expertise but also learn more from cutting-edge projects such as the Moorfields – DeepMind collaboration, which is pioneering new diagnostic approaches to eye diseases which affect millions worldwide.”